parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	25 Parkinson's papers of 530	0.57
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 7610

receipt 7619: PON2 in dopamine neurons, braak

power: full sample -0.15 (p 0.544, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.781, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.741, n 18). could be the mix.
skeptic: leave-one-out range -0.30 to -0.05, sign flips 0; without severely affected donors -0.15 (p 0.544, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PON2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7618: PON2 in astrocytes, braak

power: full sample +0.32 (p 0.194, n 18), 95% CI -0.17 to +0.69. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.31 (p 0.218, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.29 (p 0.250, n 18). could be the mix.
skeptic: leave-one-out range +0.23 to +0.44, sign flips 0; without severely affected donors +0.32 (p 0.194, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PON2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts